Liquidia shares slipped nearly 2% in pre-market trading after the company's mixed fourth-quarter results. While Q4 revenue of $92.02 million beat expectations, full-year revenue reached $143.3 million. However, earnings per share missed the $0.19 consensus. Investors remain optimistic, citing 3,600 unique prescriptions and a high patient conversion rate for YUTREPIA.